Armin Rehm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9612810/publications.pdf

Version: 2024-02-01

32	795	16	27
papers	citations	h-index	g-index
33 all docs	33 docs citations	33 times ranked	1263 citing authors

#	Article	IF	CITATIONS
1	Targeting the Tumor Microenvironment of Leukemia and Lymphoma. Trends in Cancer, 2019, 5, 351-364.	7.4	67
2	Human Cytomegalovirus Gene Products US2 and US11 Differ in Their Ability To Attack Major Histocompatibility Class I Heavy Chains in Dendritic Cells. Journal of Virology, 2002, 76, 5043-5050.	3.4	65
3	Access to Follicular Dendritic Cells Is a Pivotal Step in Murine Chronic Lymphocytic Leukemia B-cell Activation and Proliferation. Cancer Discovery, 2014, 4, 1448-1465.	9.4	60
4	Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood, 2011, 118, 1020-1033.	1.4	57
5	The Golgi Protein RCAS1 Controls Cell Surface Expression of Tumor-associated O-Linked Glycan Antigens. Journal of Biological Chemistry, 2003, 278, 22998-23007.	3.4	56
6	The ratio between dendritic cells and T cells determines the outcome of their encounter: Proliferationversus deletion. European Journal of Immunology, 2005, 35, 2851-2863.	2.9	55
7	EBAG9 Adds a New Layer of Control on Large Dense-Core Vesicle Exocytosis via Interaction with Snapin. Molecular Biology of the Cell, 2005, 16, 1245-1257.	2.1	39
8	CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. Molecular Therapy, 2018, 26, 1906-1920.	8.2	38
9	Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR TÂcells. Molecular Therapy - Methods and Clinical Development, 2022, 25, 311-330.	4.1	33
10	Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia. Cancer Research, 2016, 76, 5253-5265.	0.9	29
11	CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells. Nature Communications, 2021, 12, 240.	12.8	28
12	Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs. Journal of Molecular Medicine, 2012, 90, 1237-1245.	3.9	24
13	Dysregulated development of ILâ€17―and ILâ€21â€expressing follicular helper T cells and increased germinal center formation in the absence of RORγt. FASEB Journal, 2016, 30, 761-774.	0.5	24
14	FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma. Blood, 2019, 134, 3214-3214.	1.4	20
15	Identification of a chemokine receptor profile characteristic for mediastinal large B ell lymphoma. International Journal of Cancer, 2009, 125, 2367-2374.	5.1	19
16	FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma. Blood, 2020, 136, 4-5.	1.4	19
17	Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker. BMC Cancer, 2005, 5, 47.	2.6	18
18	Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth. Frontiers in Immunology, 2020, 11, 591741.	4.8	18

#	Article	IF	CITATIONS
19	Dendritic cell-mediated survival signals in $E\hat{1}\frac{1}{4}$ -Myc B-cell lymphoma depend on the transcription factor C/EBP $\hat{1}^2$. Nature Communications, 2014, 5, 5057.	12.8	17
20	The tumor-associated antigen EBAG9 negatively regulates the cytolytic capacity of mouse CD8+ T cells. Journal of Clinical Investigation, 2009, 119 , $2184-203$.	8.2	16
21	Accelerating clinical-scale production of BCMA CAR TÂcells with defined maturation stages. Molecular Therapy - Methods and Clinical Development, 2022, 24, 181-198.	4.1	14
22	The transcription factor $C/EBP\hat{l}^2$ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26328-26339.	7.1	13
23	Lymphoma Angiogenesis Is Orchestrated by Noncanonical Signaling Pathways. Cancer Research, 2020, 80, 1316-1329.	0.9	12
24	MACC1 regulates clathrin-mediated endocytosis and receptor recycling of transferrin receptor and EGFR in colorectal cancer. Cellular and Molecular Life Sciences, 2021, 78, 3525-3542.	5 . 4	12
25	Lymphocyte access to lymphoma is impaired by high endothelial venule regression. Cell Reports, 2021, 37, 109878.	6.4	9
26	Role of EBAG9 protein in coat protein complex lâ€dependent glycoprotein maturation and secretion processes in tumor cells. FASEB Journal, 2010, 24, 4000-4019.	0.5	7
27	The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival. Oncolmmunology, 2017, 6, e1323155.	4.6	7
28	Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells. International Journal of Molecular Sciences, 2022, 23, 903.	4.1	7
29	Dual Chimeric Antigen Receptor Approach Combining Novel Tumor Targeting Strategies Circumvents Antigen Escape in Multiple Myeloma. Blood, 2021, 138, 1718-1718.	1.4	5
30	EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice. JCI Insight, 2022, , .	5.0	2
31	EBAG9 silencing exerts an immune checkpoint function without aggravating adverse effects. Molecular Therapy, 2022, 30, 3358-3378.	8.2	2
32	Analyses of murine lymph node endothelial cell subsets using single-cell RNA sequencing and spectral flow cytometry. STAR Protocols, 2022, 3, 101267.	1.2	1